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Abstract 
Background and aims: NTproBNP and BNP levels are reduced in obese subjects, but population-based data com-
paring the pattern of this relationship in the full spectrum of insulin-resistance mediated conditions, overweight/obe-
sity, metabolic syndrome and diabetes, are limited.
Methods: The study-base were 3244 individuals aged 45–74 years, none of whom had heart failure, 1880 without 
diabetes and 1364 with diabetes, identified as part of two surveys of the population-based Casale Monferrato Study. 
All measurements were centralized. We examined with multiple linear regression and cubic regression splines the 
relationship between NTproBNP and BMI, independently of known risk factors and confounders. A logistic regression 
analysis was also performed to assess the effect of overweight/obesity (BMI ≥ 25 kg/m2), diabetes and metabolic 
syndrome on NTproBNP values.
Results: Out of the overall cohort of 3244 people, overweight/obesity was observed in 1118 (59.4%) non-diabetic 
and 917 (67.2%) diabetic subjects, respectively. In logistic regression, compared to normal weight individuals, those 
with a BMI ≥ 25 kg/m2 had a OR of 0.70 (95% CI 0.56–0.87) of having high NTproBNP values, independently of dia-
betes. As interaction between diabetes and NTproBNP was evident (p < 0.001), stratified analyses were performed. 
Diabetes either alone or combined with overweight/obesity or metabolic syndrome enhanced fourfold and over the 
OR of having high NTproBNP levels, while the presence of metabolic syndrome alone had a more modest effect (OR 
1.54, 1.18–2.01) even after having excluded individuals with CVD. In the non-diabetic cohort, obesity/overweight and 
HOMA-IR ≥ 2.0 decreased to a similar extent the ORs of high NTproBNP [0.76 (0.60–0.95) and 0.74 (0.59–0.93)], but the 
association between overweight/obesity and NTproBNP was no longer significant after the inclusion into the model 
of HOMA-IR, whereas CRP > 3 mg/dl conferred a fully adjusted OR of 0.65 (0.49–0.86).
Conclusions: NT-proBNP levels are lower in overweight/obesity, even in those with diabetes. Both insulin-resistance 
and chronic low-grade inflammation are involved in this relationship. Further intervention studies are required to 
clarify the potential role of drugs affecting the natriuretic peptides system on body weight and risk of diabetes.
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Background
Epidemiological studies have pointed out that obese 
individuals have lower plasma levels of natriuretic pep-
tides than those with normal weight, despite the higher 
prevalence of hypertension and left ventricular hyper-
trophy [1–4]. Natriuretic peptides have natriuretic and 
vasodilatory properties and beneficial actions on cardiac 
remodeling, so that the inverse relationship with BMI 
has been hypothesized to reflect a “natriuretic handicap”, 
with a reduced response to cardiac wall stress contrib-
uting to the initiation and progression of cardiovascular 
complications [5–7]. Consistently, in obese individuals 
NTproBNP plasma levels maintain significant prognostic 
information on the risk of developing heart failure, but 
equivalent accuracy is provided by lower thresholds val-
ues than in normal weight individuals [8–10].
Low circulating natriuretic peptides levels may results 
by abnormalities at various steps, including reduced 
cardiac secretion, reduced natriuretic type A receptor 
(NPRA) tissue signaling and increased systemic and tis-
sue clearance by natriuretic peptide clearance receptor 
(NPRC) and neprilysin [11]. Moreover, genetic polymor-
phism in natriuretic peptide receptor sequences has also 
been shown, which might be involved in increased clear-
ance and reduced circulating levels in homozygous C/C 
carriers [12]. Interestingly, prospective population-
based studies have shown that low natriuretic peptides 
levels are associated with an increased risk of diabetes 
incidence [12–14] and an inverse relationship between 
natriuretic peptide and insulin sensitivity has also been 
found [15–17]. Further, in overweight and obese persons 
natriuretic peptides levels increase after either lifestyle 
intervention that reduced weight or bariatric surgery 
[18–22], although circulating levels remain lower than in 
persons with cardiovascular diseases.
Altogether, these findings suggest the alternative 
hypotheses that natriuretic peptides might act as either 
marker or risk factor of insulin-resistance mediated con-
ditions, obesity, metabolic syndrome and diabetes [23]. 
However, data referring to the relationship between 
metabolic syndrome and natriuretic peptides are contro-
versial, with studies showing both increased and reduced 
natriuretic peptides levels [24–27]. As regards to dia-
betes, increased plasma levels of NTproBNP have been 
identified as the strongest independent predictor of car-
diovascular mortality even in people without pre-existing 
clinical CVD [28–30]. The paradox of both low and high 
levels of natriuretic peptides in different insulin-resist-
ance mediated conditions such as obesity and diabetes, 
is intriguing. It has been suggested that an underlying 
dysregulation causing low natriuretic peptides might 
contribute to the increased metabolic and cardiovascular 
risk of insulin-resistant conditions, whereas the presence 
of subclinical CVD might be responsible of dragging 
NTproBNP values in the opposite direction, although 
they remain inadequate [31–33]. At present, however, 
studies comparing plasma levels of NTproBNP in popula-
tion-based cohorts of both diabetic and non diabetic peo-
ple are very limited [31], whereas clinic-based studies are 
potentially biased by both low numbers of examined peo-
ple and limited generalizability of results. Therefore, the 
role of BMI on natriuretic peptide levels in people with 
and without diabetes has not been fully explored. In this 
paper we aimed to assess: (1) the cross-sectional relation-
ship between BMI and NTproBNP in the full spectrum of 
metabolic diseases mediated by insulin-resistance, over-
weight/obesity, metabolic syndrome and diabetes; 2) the 
effect of CVD on NTproBNP levels in these conditions.
Methods
The Casale Monferrato Study is an ongoing population-
based study with extensive characterization of cardio-
vascular risk factors in both diabetic and non-diabetic 
people in a representative Italian population [28, 34]. In 
this report we have examined the relationship between 
NTproBNP and insulin-resistance mediated conditions, 
overweight/obesity, metabolic syndrome and type 2 
diabetes.
The study-base were persons aged 45–74  years iden-
tified as part of two surveys of the population-based 
Casale Monferrato Study. The first survey recruited a dia-
betic cohort of 2315 people residents in 2000 in the town 
of Casale Monferrato, North-West of Italy (93,477 inhab-
itants) [28]. Out of them, centralized NTproBNP meas-
urements were available in 1364 (59% of this cohort). The 
second survey recruited a non diabetic cohort from an 
age- and sex stratified sample of 3700 individuals, ran-
domly identified in 2005–2006 through the files of the 
resident population of Casale Monferrato, after having 
excluded those with a previous diagnosis of diabetes or 
neoplastic diseases [34]. They received a letter and were 
further contacted by their general practitioner. Out of 
3700 invited people, 2293 (62%) agreed to be interviewed 
and examined at the diabetes clinic. NTproBNP measure-
ments were available in 1880 (82%). Therefore, present 
analyses included 3244 individuals aged 45–74  years, 
none of whom had heart failure, 1880 without diabetes 
and 1364 with diabetes.
The study protocol conforms to the ethical guide-
lines of the 1975 Declaration of Helsinki and the study 
protocol has been approved by the institutional ethical 
review committee. All patients were interviewed and 
examined, after having provided informed consent, at 
the local diabetes clinic of the S. Spirito Hospital, by 
trained investigators. Weight and height were measured 
with subjects not wearing shoes. Waist circumference 
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was measured at the midpoint between the lower rib 
and the iliac crest and central obesity defined as values 
> 102 cm in men and > 88 cm in women. All laboratory 
determinations were centralized. Venous blood samples 
were collected after overnight fasting for determination 
of triglycerides, total cholesterol, high-density lipopro-
tein (HDL) cholesterol (enzymatic colorimetric method 
after precipitation with  Mn2+). Low-density lipoprotein 
(LDL) cholesterol was calculated from the Friedewald’s 
formula for all persons in the cohort whose triglycer-
ide values were <  4.48  mmol/l. The albumin excretion 
rate (AER) was calculated on the basis of the urinary 
albumin concentration measured in a single, timed, 
overnight urine sample by the nephelometric method 
(Behring Nephelometer Analyzer, Behring Institute, 
Marburg, Germany), after exclusion of urinary tract 
infection, congestive heart failure and other known 
causes of non diabetic renal disease. High-sensitivity 
CRP levels were measured using an immunoturbidi-
metric method (Roche Diagnostic). Serum NTproBNP 
levels were measured by a two-site sandwich electro-
chemiluminescence immunoassay (Elecsys proBNP 
II, Roche Diagnostic, Mannheim, Germany), using a 
Modular Analytics Evo analyzer with a E170 module 
(Roche). The intra-assay variation was below 3.0% and 
total CV ranges between 2.2 and 5.8% in low and high 
ranges of NTproBNP. Serum insulin was measured with 
radioimmunoassay in the non diabetic cohort only. 
The degree of insulin sensitivity was determined by the 
HOMA-IR, using the formula: fasting plasma glucose 
(mmol/l) times fasting serum insulin (mU/L) divided 
by 22.5. Blood pressure was measured with mercury 
sphygmomanometers to the nearest 2  mmHg, in the 
right arm at the start of examination, in sitting posi-
tion, three consecutive times after an initial 5-min rest. 
Reported values are the average of second and third 
readings (phase 1 for systolic and phase 5 for diastolic 
pressure). Hypertension was defined as systolic blood 
pressure >  140  mmHg and/or diastolic blood pressure 
>  90  mmHg or treatment with antihypertensive drugs. 
Cardiovascular disease (CVD) was defined as physician 
diagnosed myocardial infarction, coronary artery bypass 
graft, stroke, arterial disease of lower limb or epiaortic 
trunks. The Rose questionnaire was also administered 
to allow the identification of people with symptoms 
suggestive of CVD (angina, IMA and arterial disease of 
lower limb). Coronary heart disease was also defined, 
on the basis of electrocardiographic abnormalities 
according to the Minnesota code, as probable (major 
Q and QS items, codes 1.1 and 1.2) or possible (minor 
Q and QS items, S-T/T items, codes 1.3, 4.1–4.4, 5.1–
5.3). The diagnosis, however, had then to be confirmed 
by general practitioner/specialist according to stand-
ard examinations for these diseases. Smoking habit was 
classified into one of three categories: never smoker, 
ex-smoker if patient stopped smoking at least 1 month 
before the visit, and smoker. In the non diabetic cohort 
data on physical activity were assessed through a modi-
fied version of the International Physical Activity Ques-
tionnaire, including three question regarding activity at 
work, travel to and from places and recreational activi-
ties. The diagnosis of metabolic syndrome was defined 
according to the updated National Cholesterol Educa-
tion Program’s Adult Treatment Panel III report.
Statistical analyses
Variables distributed normally are presented as mean 
and standard deviation (SD), whereas variables with 
skewed distribution were analysed after natural logarith-
mic transformation (triglycerides, AER, creatinine, CRP, 
NTproBNP, HOMA-IR) and results presented as geo-
metric means and interquartile range. Pearson correla-
tions between NTproBNP and continuous variables were 
also performed. To explore the shape of the association 
between NTproBNP and BMI, we modeled NTproBNP 
as a restricted cubic spline in a multivariate linear model 
with BMI as dependent variable, adjusted for known 
risk factors and confounders (age, sex, hypertension, 
LDL-cholesterol, smoke, CRP, waist circumference, 
AER, creatinine, CVD). As in multiple linear regression 
we found a significant test of interaction between dia-
betes and NTproBNP (p  <  0.0001), we performed sepa-
rately analyses in diabetic and non diabetic people. In 
the whole cohort, we tested also the potential role of uric 
acid, HDL-cholesterol, triglycerides and that of a cat-
egorical variable with four levels determined by the com-
bined effect of diabetes (yes/no) and overweight/obesity 
(BMI < 25 and ≥ 25 kg/m2). In non diabetic people, we 
tested the effect of HOMA-IR and physical activity and, 
in diabetic people, that of HbA1c, diabetes duration and 
diabetes treatment. All analyses were also performed 
after having excluded individuals with clinical CVD.
A logistic regression analysis was performed to assess 
the relationship between BMI (<  25 and ≥  25  kg/m2, 
dependent variable) and quartiles of NTproBNP (< 6.40, 
6.40–33.9, 34.0–89.9, > 89.9 pg/ml), independently of age, 
sex, diabetes, hypertension, LDL-cholesterol, waist cir-
cumference, smoke, CRP, AER, creatinine, CVD. As ORs 
in the upper quartiles of NTproBNP were similar, final 
models were performed using NTproBNP as a categorical 
dependent variable with two levels defined by its median 
value, to assess the independent ORs of overweight/obe-
sity, diabetes and metabolic syndrome. All analyses were 
performed with Stata Release 10.0.
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Results
Overweight/obesity (BMI ≥  25  kg/m2) was observed in 
1118 (59.4%) of non-diabetic and 917 (67.2%) of diabetic 
subjects, respectively. Obesity (BMI  ≥  30  kg/m2) was 
observed in 345 (18.3%) of non diabetic and 469 (34.4%) 
of diabetic subjects. As shown in Table  1, significant 
differences among subgroups were evident, with over-
weight/obese people having the worst cardiovascular risk 
profile compared to normal weight people, irrespective of 
diabetes status. Among people with diabetes, NTproBNP 
levels were significantly lower in overweight/obese com-
pared to normal weight subjects, but this difference was 
not observed in non diabetic subjects.
No significant correlation between NTproBNP and 
either BMI or waist circumference was found. In non 
diabetic people, NTproBNP values were positively corre-
lated with age (r = 0.15, p < 0.0001) and AER (r = 0.05, 
p  =  0.02) and negatively with HOMA-IR (r  =  −0.06, 
p = 0.02) and CRP (r = −0.07, p = 0.02). In diabetic peo-
ple, we found significant positive correlations with age 
(r =  0.38, p  <  0.0001), creatinine (r =  0.22, p  <  0.001), 
CRP (r = 0.17, p < 0.001), AER (r = 0.15, p < 0.001) and 
systolic blood pressure (r = 0.08, p = 0.004).
We explored the existence of a non linear relation-
ship between NTproBNP and BMI using cubic regres-
sion splines with knots at quintiles of distribution of 
NTproBNP, but no evidence was found of either non 
linear or curvilinear relationships, after multiple adjust-
ments including diabetes. As interaction between 
NTproBNP and diabetes was significant (p  <  0.001), 
multiple linear regression analyses were performed sep-
arately for diabetes and non diabetes. In non diabetic 
people, BMI was negatively associated with NTproBNP 
(β = −0.02 p = 0.03), independently of age, sex, creati-
nine, AER, CRP, smoke, physical activity, hypertension, 
LDL-cholesterol and CVD, but this association reverted 
Table 1 Characteristics of the Casale Monferrato population-based cohort, by BMI and diabetes
Data are mean ± standard deviation and geometric means (interquartile range)
Non diabetes (n = 1880) Type 2 diabetes (n = 1364)
BMI < 25 kg/m2 
(n = 762)
BMI ≥ 25 kg/m2 
(n = 1118)
p value BMI < 25 kg/m2 
(n = 447)
BMI ≥ 25 kg/m2 
(n = 917)
p value
Age (years) 60.1 ± 8.3 61.4 ± 8.0 0.0007 64.7 ± 7.7 63.6 ± 8.0 0.01
Body mass index (kg/
m2)
22.3 ± 2.0 28.9 ± 3.4 < 0.0001 23.8 ± 1.8 31.3 ± 4.6 < 0.0001
Waist circumference 
(cm)
80.9 ± 9.3 97.6 ± 9.7 < 0.0001 89.9 ± 10.5 103.2 ± 10.6 < 0.0001
Glucose (mmol/l) 4.99  ± 0.74 5.41  ± 1.18 < 0.0001 9.80 ± 3.31 9.89 ± 3.04 0.60
Total cholesterol 
(mmol/l)
5.69 ± 0.95 5.69 ± 1.02 0.89 5.60 ± 1.05 5.47 ± 1.03 0.08
LDL cholesterol 
(mmol/l)
3.29 ± 0.85 3.40 ± 0.90 0.007 3.39 ± 0.90 3.32 ± 0.88 0.24
HDL cholesterol 
(mmol/l)
1.88 ± 0.46 1.62 ± 0.40 < 0.0001 1.49 ± 0.41 1.34 ± 0.34 < 0.0001
Triglycerides (mmol/l) 1.01 (0.72–1.32) 1.32 (0.94–1.80) < 0.0001 1.36 (0.94–1.91) 1.59 (1.10–2.15) < 0.0001
Creatinine (µmol/l) 68.9 (60.1–78.7) 78.7 (64.5–84.9) < 0.0001 84.9 (62.8–84.9) 72.5 (64.5–84.9) 0.007
CRP mg/l 0.11 (0.06–0.19) 0.22 (0.12–0.39) < 0.0001 0.22 (0.10–0.48) 0.31 (0.14–0.67) < 0.0001
Uric acid (µmol/l) mg/dl 269.44 ± 73.16 325.36 ± 80.3 < 0.0001 326.55 ± 146.32 333.68 ± 90.41 0.30
Systolic blood pressure 
(mmHg)
141.6 ± 20.4 150.1 ± 18.9 < 0.0001 143.3 ± 16.5 146.3 ± 16.1 0.001
Diastolic blood pressure 
(mmHg)
87.5 ± 10.5 93.0 ± 11.0 < 0.0001 81.2 ± 8.5 83.5 ± 8.2 < 0.0001
Hypertension (%) 479 (62.9%) 951 (85.1%) < 0.0001 375 (84.6%) 830 (90.5%) < 0.0001
People treated with
 Diuretics 83 (10.9%) 260 (23.3%) < 0.001 119 (26.6%) 338 (36.7%) < 0.001
 ACE-inhibitors 82 (10.8%) 215 (19.2%) < 0.001 153 (34.2%) 397 (43.3%) < 0.001
 ARBs 28 (2.3%) 83 (4.1%) 0.008 41 (9.2%) 107 (11.7%) 0.16
 AER (µg/min) 3.4 (2.0–5.1) 4.6 (2.6–6.6) < 0.0001 11.8 (4.2–23.9) 13.6 (4.5–30.5) 0.16
 Smokers 141 (18.5%) 342 (30.6%) < 0.0001 113 (25.9%) 303 (34.3%) < 0.0001
 CVD 23 (3.0%) 82 (7.3%) < 0.001 90 (20.1%) 203 (22.1%) 0.40
 NTproBNP (pg/ml) 14.6 (5–39.5) 13.4 (5–30.9) 0.13 77.3 (32–164) 62.4 (29–133) 0.006
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to non significance after further adjustment for CRP, 
which was negatively related to NTproBNP (β = −0.15, 
p  =  <  0.0001). In diabetic people, waist circumfer-
ence was negatively related to NTproBNP (β = −0.006, 
p  =  0.04), and after further adjustment for CRP, β 
increased to −0.01 (p = 0.003), whereas CRP conferred 
a β value of 0.12 (p < 0.001). In this model, the categorical 
variable defining central obesity conferred a β of −0.24 
(p  =  0.001). HbA1c, diabetes duration and diabetes 
treatment did not contribute significantly to the model. 
Results were virtually identical limiting analyses to peo-
ple without CVD.
Multiple linear regression analysis was then performed 
in the whole cohort to assess the individual and combined 
effect on NTproBNP values of a categorical variable with 
four levels defined by either individual or combined pres-
ence of overweight/obesity and diabetes, independently 
of other risk factors, obtaining the following results: non 
diabetes and overweight/obesity, β = −0.12 (p =  0.03); 
diabetes and normal weight, β = 1.28, (p < 0.0001); dia-
betes and overweight/obesity β = 1.03 (p < 0.0001). After 
further adjustment for CRP, the β value of the category 
defined by non diabetes and overweight/obesity reverted 
to non statistical significance (p = 0.06).
In a logistic regression model examining the relation-
ship between overweight/obesity (dependent variable) 
and quartiles of NTproBNP, independently of diabetes 
and other confounders, we obtained the following ORs: 
0.84 (0.64–1.11), 0.68 (0.50–0.93) and 0.53 (0.37–0.77). 
Therefore, final analyses were performed using 
NTproBNP as a dependent categorical variable with two 
levels defined by its median value (34.0  pg/ml) assess-
ing the independent ORs of having high NTproBNP by 
metabolic categories (Table  2). Model 1 explored the 
individual effect of BMI and diabetes. As compared to 
normal-weight individuals, those with a BMI  ≥  25  kg/
m2 had an adjusted OR of 0.70 (95% CI 0.56–0.87), inde-
pendently of diabetes, whereas individuals with diabetes 
showed a 2.6-fold increase in the adjusted OR compared 
to non diabetic subjects, independently of BMI. We then 
examined the effect of diabetes combined with over-
weight/obesity (Model 2), and that of the metabolic syn-
drome (Model 3). In people with overweight/obesity only, 
the OR of having NTproBNP levels above the median 
value was significantly lower than in normal weight sub-
jects (Model 2). The presence of diabetes either alone or 
combined with overweight/obesity (Model 2) or meta-
bolic syndrome (Model 3) greatly enhanced the OR of 
having NTproBNP levels above the median value, while 
the presence of metabolic syndrome alone had a more 
modest effect (OR 1.54, 1.18–2.01). All previous results 
were virtually identical after the exclusion of subjects 
with CVD.
Finally, we performed a separate analysis in the 
non-diabetic cohort to examine the effect of HOMA-
IR values above median value (≥  2.0) on NTproBNP 
(Table  3), after having excluded individuals with CVD. 
As shown in Model 1, BMI  ≥  25  kg/m2 and HOMA-
IR ≥ 2.0 decreased to a similar extent the ORs of having 
NTproBNP above the median value (BMI OR 0.70, 95% 
CI 0.55–0.89, HOMA-IR OR 0.68, 0.54–0.87). How-
ever, the association between overweight/obesity and 
Table 2 Adjusted odds ratios (ORs) of  having NTproBNP 
levels above  median value (34  pg/ml) in  people aged 
45–74  years in  the population-based Casale Monferrato 
Study
* ORs are adjusted age, sex, waist circumference, plasma creatinine, 
hypertension, LDL-cholesterol, smoke, CRP, AER and CVD
Adjusted OR* (95% CI)
Model 1
 BMI < 25 kg/m2 1.00
 BMI ≥ 25 kg/m2 0.70 (0.56–0.87)
 Non diabetes 1.00
 Diabetes 2.60 (2.37–2.87)
 People without CVD
   BMI < 25 kg/m2 1.00
   BMI ≥ 25 kg/m2 0.67 (0.53–0.86)
   Non diabetes 1.00
   Diabetes 2.47 (2.23–2.74)
Model 2
 Non diabetes, BMI < 25 kg/m2 1.00
 Non diabetes, BMI ≥ 25 kg/m2 0.63 (0.48–0.82)
 Diabetes, BMI < 25 kg/m2 5.44 (3.98–7.44)
 Diabetes, BMI ≥ 25 kg/m2 4.42 (3.25–6.01)
 P for trend < 0.0001
 People without CVD
  BMI < 25 kg/m2 1.00
  BMI ≥ 25 kg/m2 0.64 (0.48–0.88)
  Non diabetes 5.47 (3.93–7.62)
  Diabetes 4.13 (2.99–5.72)
  P for trend < 0.0001
Model 3
 Neither Metabolic syndrome nor diabetes 1.00
 Metabolic syndrome 1.67 (1.25–2.22)
 Diabetes 7.45 (5.54–10.01)
 Metabolic syndrome + diabetes 7.56 (5.84–9.78)
 P for trend < 0.0001
 People without CVD
  Neither Metabolic syndrome nor diabetes 1.00
  Metabolic syndrome 1.99 (1.48–2.69)
  Diabetes 7.49 (5.47–10.3)
  Metabolic syndrome + diabetes 7.52 (5.70–9.92)
  P for trend < 0.0001
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NTproBNP was marginally not significant after the inclu-
sion into the model of HOMA-IR (Model 2). CRP was 
negatively associated with NTproBNP and this effect was 
evident even in the fully adjusted model (Model 4).
Discussion
This study assessed the cross-sectional relationship 
between NTproBNP and insulin-resistance associated 
conditions—overweight/obesity, metabolic syndrome, 
and diabetes—in the large population-based cohort of 
diabetic and non-diabetic individuals from the Casale 
Monferrato Study. We provided evidence that over-
weight/obese subjects had a 30% lower OR of having 
NTproBNP levels above median values compared to 
normal weight individuals (Table 2, Model 1). This find-
ing, which was independent of the presence of diabetes 
and other confounders, such as chronic renal failure, was 
evident even after having excluded people with clinical 
CVD. Therefore, we provide further evidence supporting 
the hypothesis of a “natriuretic handicap” in overweight/
obese individuals, which is evident even in those with 
diabetes, although higher prevalence of subclinical CVD 
would force natriuretic peptides levels in the opposite 
direction [5–7]. Our findings are in agreement with pre-
vious epidemiological studies that consistently showed a 
negative association between BMI and NTproBNP levels 
in non diabetes [1–4, 35], whereas data including diabe-
tes are more limited [31–33]. The cause of the relative 
BNP/NTproBNP deficiency in obesity (natriuretic handi-
cap) is poorly understood, and several mechanisms have 
been suggested, including reduced BNP synthesis/release 
from the heart and increased peripheral degradation 
[5–7]. Natriuretic peptides are cleared and degradated 
by neutral endopeptidase neprilysin and NPRC [23]. 
Interestingly, insulin has been observed to induce NPRC 
expression in human adipocytes [36, 37], and this finding 
might link conditions associated with hyperinsulinemia, 
such as obesity and insulin-resistance. Moreover, neprily-
sin, the natriuretic peptides degrading endopeptidase, is 
expressed at increased levels in obesity [38]. On the other 
hand, there is also emerging evidence that natriuretic 
peptides control metabolic processes by enhancing lipol-
ysis and energy expenditure, acting at mitochondrial level 
[39]. Therefore, low NTproBNP levels in overweight/obe-
sity may be not only a consequence, but also a cause of 
obesity. Indeed, low levels of NTproBNP might lead to 
reduced lipolysis and excessive weight gain, which may 
be one of the biological alterations that contribute to the 
development of metabolic syndrome [11]. From a clinical 
point of view, however, it is relevant to notice that even 
in obese individuals NTproBNP levels provide significant 
prognostic information of risk of developing heart failure 
[8, 9]. Indeed, lower cut-off values in obese individuals 
have been found to provide equivalent accuracy to values 
applied for non obese individuals, and this further sup-
port the “natriuretic handicap” hypothesis, with reduced 
response to cardiac wall stress associated with obesity 
[8].
Insulin resistance, CRP and NTproBNP
In our study the inverse association between BMI and 
NTproBNP, observed in non-diabetic patients without 
CVD, was no longer significant after the inclusion of 
insulin resistance (HOMA-IR) into the model (Table  3, 
Model 2), confirming that insulin-resistance is impor-
tant in linking overweight/obesity to reduced NTproBNP 
levels. This finding has been previously observed in two 
large community-based studies, the Framingham Heart 
Study and the Malmo Diet and Cancer study, show-
ing that the inverse relationship between obesity and 
NTproBNP was attenuated after adjustment for HOMA-
IR [15]. Moreover, this relationship was evident not only 
in obese but also in non obese individuals [15]. Even in 
the elderly, the Cardiovascular Health Study showed that 
lower NTproBNP levels were associated with higher insu-
lin resistance in individuals without heart failure, CHD 
and chronic kidney disease [16]. In the intervention Dia-
betes Prevention Program study, circulating NTproBNP 
was associated with a measure of insulin sensitivity 
before and during preventive interventions regardless of 
whether a participant was treated with placebo, intensive 
lifestyle intervention or metformin [17]. Statin treatment 
Table 3 Adjusted odds ratios (ORs) of  having NTproBNP levels above  median value (34  pg/ml) in  non diabetic people 
aged 45–74 years without CVD, in the population-based Casale Monferrato Study
Variables were included separately in model 1 and simultaneously in all other models
* ORs are adjusted age, sex, waist circumference, physical activity, plasma creatinine, hypertension, LDL-cholesterol, smoke, CRP, and AER
Adjusted OR* (95% CI)
Model 1 Model 2 Model 3 Model 4
BMI ≥ 25 kg/m2 0.70 (0.55–0.89) 0.78 (0.61–1.01) 0.83 (0.64–1.08)
HOMA-IR ≥ 2.04 0.68 (0.54–0.87) 0.74 (0.58–0.96) 0.74 (0.58–0.94) 0.78 (0.61–1.01)
CRP > 3 mg/l 0.59 (0.45–0.78) 0.63 (0.47–0.83) 0.65 (0.49–0.86)
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has also been reported to induce insulin resistance and, 
in line with previous findings, a small clinic-based study 
found that the inverse relationship between NTproBNP 
and HOMA-IR was limited to individuals treated with 
statin [40]. Altogether, these findings provides further 
support to the current hypothesis that NTproBNP acts 
as marker of insulin sensitivity, independently of BMI. 
However, only prospective studies assessing whether 
directly altering BNP concentrations influence metabolic 
risk would allow to disentangle the role of natriuretic 
peptides as marker or determinant of insulin sensitivity.
As a chronic low-grade inflammation triggered by 
adipocyte hypertrophy is considered an important 
mechanism coupling an unhealthy excess body fat to 
insulin-resistance [41], we have also explored the poten-
tial role of CRP, a marker of chronic inflammation. In 
non-diabetic patients, CRP values were inversely cor-
related with NTproBNP levels and this inverse relation-
ship was confirmed in logistic regression, independently 
of other risk factors. Importantly, the inverse association 
between NTproBNP and both BMI and insulin resist-
ance was no longer significant after the inclusion of 
CRP into the logistic regression model (Table  3, Model 
4) consistently with the hypothesis that obesity-related 
insulin resistance is, at least in part, a chronic inflamma-
tory disease initiated in adipose tissue [42]. Our finding 
of a negative relationship between CRP and NTproBNP 
in non diabetic people likely reflects the role of CRP as 
marker of other abnormalities directly affecting circu-
lating NTproBNP and related to adiposity. We did not 
examine the roles of adiposite generated cytokines, such 
as tumor necrosis factor-α, interleukin-1 (IL-1) and IL-6, 
promoting the release of CRP, but it is known that BNP is 
upregulated at the transcriptional and translational levels 
by pro-inflammatory cytokines in cardiac myocytes [43]. 
Moreover, a recent study found a significant positive cor-
relation between the plasma BNP and serum CRP levels 
in cancer patients as well as cancer model mice without 
overt heart failure, linking also cancer-related chronic 
inflammation and natriuretic peptides [44]. In the MESA 
Study, including 5597 individuals (12% with diabetes), 
IL-6 was positively associated with NTproBNP through-
out its whole range of values [31]. In our study, CRP 
values were twofold higher in individuals with diabetes 
(42% of the overall cohort) than in those without diabetes 
and a positive correlation between CRP and NTproBNP 
was also found in diabetes only, consistently with higher 
prevalence of CVD in diabetes, and increased release of 
cytokines and CRP production [43, 45]. In line with these 
findings, in the EURODIAB Prospective Complications 
Study we previously showed with multivariate analyses 
that increased NTproBNP values in type 1 diabetes com-
plications were explained by increased TNF-α levels [46].
Diabetes and NTproBNP
People with diabetes had a 2.6-fold increased OR of hav-
ing NTproBNP values above median levels as compared 
to people without diabetes, independently of BMI, con-
founders and risk factors (Table  2, Model 1). Because 
diabetes and BMI exert opposite effects on NTproBNP, 
the independent association between diabetes and 
NTproBNP was much stronger in normal-weight sub-
jects (Table 2, Model 2) whereas people with overweight/
obesity had 30% higher likelihood of having lower levels. 
Moreover, in multiple linear regression central obesity 
was negatively associated with NTproBNP levels, inde-
pendently of other confounders. Therefore, the effect 
of diabetes prevailed on that of BMI and NTproBNP 
values were reduced in people with both diabetes and 
overweight/obesity, pointing out the existence of a likely 
natriuretic handicap even in diabetic subjects [23]. Con-
sistently, different BNP threshold have been identified in 
diabetic compared to non diabetic patients to maintain 
equivalent accuracy in screening for stage B heart failure 
[47].
In our study the issue of a direct relationship between 
diabetes and NTproBNP is clinically relevant as 
NTproBNP is a potent marker and predictor of vascular 
complications [28–30, 46]. This relationship was inde-
pendent of CVD, AER, serum creatinine, and hyperten-
sion. Therefore, the rise in NTproBNP levels was not 
explained by the presence of cardiovascular and renal 
chronic complications of diabetes and/or by hemody-
namic changes that are known to enhance NTproBNP 
levels. Diabetes may induce alterations in natriuretic pep-
tides processing and/or clearance resulting in enhanced 
NTproBNP circulating levels [39]. Alternatively, subclini-
cal pathological processes occurring in the cardiovascular 
system of diabetic patients may enhance BNP/NTproBNP 
levels. Consistent with this hypothesis, in the Multi-Eth-
nic Study of Atherosclerosis when subclinical CVD devel-
ops, the inverse relationship between NTproBNP and 
BMI was completely lost and NTproBNP levels rise, likely 
as the result of subclinical CVD [31]. This would also 
explain why NTproBNP is a strong predictor of diabetes 
cardiovascular complications [33]. In the whole cohort 
of the Casale Monferrato Study we found no evidence 
of either non linear or curvilinear relationship between 
NTproBNP and other variables as reported in the MESA 
study [31]. However, we found a strong modification 
effect of diabetes and this finding might be related to the 
higher frequency of individuals with diabetes examined 
in our study (42%) compared to the MESA Study (12%). 
Potential mechanisms of the rise in NTproBNP circulat-
ing levels in this setting are hypoxia, enhanced myocardial 
wall strain, and inflammatory cytokines as they have been 
shown to increase BNP production [23]. In this regard it 
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is noteworthy that in our study the correlation between 
CRP and NTproBNP, that was negative in obese/over-
weight non diabetic individuals, became positive in those 
with diabetes, even in those without pre-existing CVD, 
suggesting the effect of subclinical CVD on both CRP and 
NTproBNP plasma levels.
Metabolic syndrome and NTproBNP
The presence of metabolic syndrome increased the OR of 
having NTproBNP values above median levels (Table  3, 
Model 3) and there was a significant trend of increasing 
OR through classes of metabolic abnormalities, with the 
lowest OR observed in people who did not have either 
diabetes or metabolic syndrome and the highest OR in 
people having both. Previous data on the relationship 
between NTproBNP and the metabolic syndrome have 
been conflicting, with studies showing either lower or 
similar natriuretic peptides values compared to people 
without the metabolic syndrome [25, 26]. This is likely 
due to differences among examined populations in the 
relative frequencies of metabolic syndrome components 
with opposite effects on NTproBNP, such as obesity and 
hypertension. Consistently, in a case-cohort analysis of 
the Casale Monferrato Study we provided evidence that, 
compared to people without any component of the meta-
bolic syndrome, those in the uncomplicated phase of the 
syndrome, who had neither CVD/chonic renal failure nor 
diabetes, had yet increased NTproBNP values, even if 
they were normotensive [27].
Limitation and strength
There are certain limitations to our study. First, it is a 
cross-sectional study and this restricts our ability to 
assess temporal relationships and to identify underly-
ing causal biological mechanisms. Second, although 
people with acute heart failure were excluded, no data 
on structural and functional cardiac abnormalities were 
available and we could not adjust data either for echocar-
diographic variables such as left ventricular mass and left 
atrial size or for subclinical CVD. Third, physical activ-
ity level was examined in the non diabetic cohort only. 
Finally, we measured NTproBNP plasma levels only as a 
marker of BNP. As circulating levels of proBNP 1-108 are 
not detected by conventional BNP1-32 and NTproBNP 
assays, we cannot exclude the hypothesis of impaired 
peripheral processing to mature BNP 1-32 [23].
The strength of this analysis is the large sample size and 
broad distribution of age, increasing precision and gen-
eralizability. Indeed, our study included two large pop-
ulation-based cohorts of people living in the same area 
and examined with standardized methods, with similar 
numbers of recruited people with and without type 2 
diabetes. This allowed us to perform comparisons among 
different groups of metabolic abnormalities.
Conclusions
Altogether, these findings, although derived from a cross-
sectional study, provides further epidemiological evi-
dence towards the current hypothesis that natriuretic 
peptides are implicated in metabolic processes, with 
lower circulating levels in insulin-resistance non diabetic 
people and higher values in the upper spectrum of meta-
bolic abnormalities, diabetes with the metabolic syn-
drome. Moreover, diabetic overweight individuals have 
higher but inadequately increased levels of NTproBNP 
compared to normal weight diabetic individuals, sug-
gesting an underlying natriuretic handicap. These results 
were irrespective of presence/absence of CVD, which by 
itself increases natriuretic peptides levels. However, fur-
ther studies are required to test the possibility that new 
intervention strategies targeting the natriuretic peptides 
system may be effective in lowering not only blood pres-
sure and sodium retention, but also body weight and the 
risk of diabetes.
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